Although the implementation of PD-1 or PD-L1 immune checkpoint blockade has significantly improved lung cancer patient survival, only a minority of patients show durable response to treatment, suggesting innate or acquired resistance to immunotherapies12. This evidence concerns the gene CD274 and lung cancer.